XML 45 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable Segment Information (Tables)
 6 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment:

 

Three months ended

 

 

Six months ended

 

 

March 31

 

 

March 31

 

(In millions - unaudited)

2025

 

 

2024

 

 

2025

 

 

2024

 

SALES

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

172

 

 

$

222

 

 

$

306

 

 

$

422

 

Personal Care

 

146

 

 

 

169

 

 

 

279

 

 

 

298

 

Specialty Additives

 

134

 

 

 

157

 

 

 

249

 

 

 

279

 

Intermediates

 

37

 

 

 

40

 

 

 

71

 

 

 

73

 

Intersegment sales(a)

 

(10

)

 

 

(13

)

 

 

(21

)

 

 

(24

)

$

479

 

 

$

575

 

 

$

884

 

 

$

1,048

 

OPERATING INCOME (LOSS)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

28

 

 

$

50

 

 

$

42

 

 

$

82

 

Personal Care

 

28

 

 

 

25

 

 

 

39

 

 

 

28

 

Specialty Additives

 

7

 

 

 

(18

)

 

 

2

 

 

 

(50

)

Intermediates

 

(1

)

 

 

9

 

 

 

2

 

 

 

16

 

Unallocated and other(b)

 

(11

)

 

 

(45

)

 

 

(213

)

 

 

(72

)

 

$

51

 

 

$

21

 

 

$

(128

)

 

$

4

 

DEPRECIATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences(c)

$

22

 

 

$

11

 

 

$

31

 

 

$

20

 

Personal Care

 

7

 

 

 

9

 

 

 

15

 

 

 

17

 

Specialty Additives(d)

 

13

 

 

 

40

 

 

 

27

 

 

 

77

 

Intermediates

 

3

 

 

 

3

 

 

 

6

 

 

 

6

 

 

$

45

 

 

$

63

 

 

$

79

 

 

$

120

 

AMORTIZATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

4

 

 

$

5

 

 

$

8

 

 

$

12

 

Personal Care

 

8

 

 

 

11

 

 

 

19

 

 

 

22

 

Specialty Additives

 

3

 

 

 

4

 

 

 

5

 

 

 

6

 

Intermediates

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

$

15

 

 

$

20

 

 

$

32

 

 

$

40

 

EBITDA(e)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

54

 

 

$

66

 

 

$

81

 

 

$

114

 

Personal Care

 

43

 

 

 

45

 

 

 

73

 

 

 

67

 

Specialty Additives

 

23

 

 

 

26

 

 

 

34

 

 

 

33

 

Intermediates

 

2

 

 

 

12

 

 

 

8

 

 

 

22

 

Unallocated and other

 

(11

)

 

 

(45

)

 

 

(213

)

 

 

(72

)

 

$

111

 

 

$

104

 

 

$

(17

)

 

$

164

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31

 

 

September 30

 

(In millions - unaudited)

2025

 

 

2024

 

TOTAL ASSETS

 

 

 

 

 

Life Sciences

$

1,876

 

 

$

1,778

 

Personal Care

 

702

 

 

 

950

 

Specialty Additives

 

1,355

 

 

 

1,516

 

Intermediates

 

119

 

 

 

127

 

Unallocated and other

 

1,181

 

 

 

1,274

 

 

$

5,233

 

 

$

5,645

 

 

 

 

 

 

 
(a)
Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.
(b)
Includes a $8 million gain on sale for the three and six months ended March 31, 2025 and a $183 million impairment charge for the six months ended March 31, 2025, both related to the sale of the Avoca business within income (loss) on acquisitions and divestitures, net caption of the Statements of Condensed Consolidated Income (Loss).
(c)
Depreciation includes accelerated depreciation of $13 million for Life Sciences for the three and six months ended March 31, 2025.
(d)
Depreciation includes accelerated depreciation of $27 million and $49 million for Specialty Additives for the three and six months ended March 31, 2024, respectively.
(e)
Excludes income (loss) from discontinued operations and other net periodic benefit loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.